Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis

Table 1 The area under the curve of the estimated probability distribution

Day	AL in Africa^a 95% CI]	AL in Asia^a [95% CI]	DP in Africa (PIP mg/kg ≤ 48) [95% CI]	DP in Africa (PIP mg/kg > 48) [95% CI]
28	0.42 [0.26–0.53]	0.68 [0.55–0.85]	0.39 [0.25–0.52]	0.20 [0.00–0.36]
35	0.63 [0.40–0.78]	0.88 [0.78–0.99]	0.69 [0.53–0.83]	0.36 [0.03–0.59]
42	0.79 [0.53–0.97]	0.98 [0.93–1.00]	0.91 [0.78–1.00]	0.53 [0.10–0.81]
49	0.91 [0.64–1.00]	1.00 [0.93–1.00]	1.00 [0.93–1.00]	0.70 [0.22–0.99]
56	0.97 [0.74–1.00]	1.00 [0.94–1.00]	1.00 [0.98–1.00]	0.84 [0.36–1.00]
63	1.00 [0.81–1.00]	1.00	1.00	0.93 [0.47–1.00]

AL, artemether-lumefantrine; DP, dihydroartemisinin-piperaquine; PIP, piperaquine; CI, confidence interval
^aEstimated in children < 5 years in Africa and in patients of all ages from Asia
The 95% confidence interval was estimated from 1000 bootstrap samples of data for AL; for DP not under-dosed this was from 925 samples, and for DP under-dosed this was based on 987 bootstrap samples drawn from the original dataset

ISSN: 1475-2875